Abstract
Efaproxiral (2-[4-[[(3,5-dimethylanilino)carbonyl]methyl]phenoxyl]-2-methylpropionic acid, formerly referred to as RSR13) is prohibited in sports according to the World Anti-Doping Agency (WADA). The drug as well as structurally related compounds and a stable isotope-labeled derivative have been synthesized to elucidate the fragmentation pathway of efaproxiral, using electrospray ionization (ESI) and tandem mass spectrometry by employing a novel linear ion trap—orbitrap hybrid mass spectrometer—in positive and negative ionization modes. The elimination of 2-methyl acrylic acid (−86 u) has been identified as a major fragmentation process in both charge states. Negative ionization and collision-induced dissociation (CID) caused an additional release of carbon dioxide (−44 u), and positive ionization the loss of formic acid (−46 u). Efaproxiral was incorporated into an existing screening procedure for doping controls using solid-phase extraction (SPE) followed by liquid chromatography-tandem mass spectrometry, enabling a limit of detection of 2.5 ng/ml and interday precisions ranging from 7.9 to 13.0%. Verf.-Referat
Translated title of the contribution | Massenspektrometrische Charakterisierung von Efaproxiral (RSR13) und deren Umsetzung in der Dopingkontrolle unter Verwendung von Flüssigkeitschromatographie/Ionisation bei Atmosphärendruck/Tandem-Massenspektrometrie |
---|---|
Original language | English |
Journal | Journal of mass spectrometry : JMS |
Volume | 41 |
Pages (from-to) | 332-338 |
Number of pages | 7 |
ISSN | 1076-5174 |
Publication status | Published - 2006 |